1. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018
2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial;Schmid;Lancet Oncol,2019
3. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer;Cortes;J Clin Oncol,2020
4. Pembrolizumab for early triple-negative breast cancer;Schmid;N Engl J Med,2020
5. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98;Loi;J Clin Oncol,2013